Litcius/Paper detail

Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management

Jonathan Z. Li, Rajesh T. Gandhi

2022JAMA21 citationsDOI

Abstract

Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMonoclonal antibodyBetacoronavirusSars virusCoronavirus InfectionsAntibodyImmunologyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management | Litcius